2 results
Approved WMOCompleted
To determine whether prostate biopsies processed with the SmartBX system result in more and better interpretable material.
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.